Scherle Peggy 4
4 · Prelude Therapeutics Inc · Filed Aug 30, 2021
Insider Transaction Report
Form 4
Scherle Peggy
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2021-08-27$1.43/sh+6,014$8,600→ 178,934 total - Sale
Common Stock
2021-08-27$36.23/sh−2,707$98,085→ 173,527 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2021-08-27−6,014→ 27,018 totalExercise: $1.43Exp: 2028-11-12→ Common Stock (6,014 underlying) - Sale
Common Stock
2021-08-27$35.32/sh−2,700$95,377→ 176,234 total - Sale
Common Stock
2021-08-27$37.08/sh−607$22,505→ 172,920 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2021-08-26−1,700→ 33,032 totalExercise: $1.43Exp: 2028-11-12→ Common Stock (1,700 underlying) - Exercise/Conversion
Common Stock
2021-08-26$1.43/sh+1,700$2,431→ 174,620 total - Sale
Common Stock
2021-08-26$35.19/sh−1,700$59,819→ 172,920 total
Footnotes (7)
- [F1]Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met.
- [F2]The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F7]The stock option vested as to 25% of the total shares monthly beginning on November 13, 2019, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.